CN110755479B - 一种用于治疗关节炎的外用凝胶贴 - Google Patents
一种用于治疗关节炎的外用凝胶贴 Download PDFInfo
- Publication number
- CN110755479B CN110755479B CN201911139615.1A CN201911139615A CN110755479B CN 110755479 B CN110755479 B CN 110755479B CN 201911139615 A CN201911139615 A CN 201911139615A CN 110755479 B CN110755479 B CN 110755479B
- Authority
- CN
- China
- Prior art keywords
- parts
- gel
- stirring
- treating arthritis
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 20
- 239000011159 matrix material Substances 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000341 volatile oil Substances 0.000 claims description 12
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 11
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 11
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 11
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 11
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 11
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 11
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 11
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 11
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 11
- 229960003639 laurocapram Drugs 0.000 claims description 11
- 229940041616 menthol Drugs 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 11
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 11
- 239000000600 sorbitol Substances 0.000 claims description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 10
- 229960000913 crospovidone Drugs 0.000 claims description 10
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 10
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 10
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 6
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229960005150 glycerol Drugs 0.000 claims description 5
- 229960004063 propylene glycol Drugs 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 241000501743 Gentiana macrophylla Species 0.000 claims description 4
- 241001166194 Geranium wilfordii Species 0.000 claims description 4
- 241000195954 Lycopodium clavatum Species 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 235000008708 Morus alba Nutrition 0.000 claims description 3
- 240000000249 Morus alba Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 7
- 239000011505 plaster Substances 0.000 abstract description 7
- 239000006187 pill Substances 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 238000010579 first pass effect Methods 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000002951 depilatory effect Effects 0.000 description 5
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 4
- 229960004034 sitagliptin Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001077909 Sigesbeckia Species 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种用于治疗关节炎的外用凝胶贴，它是在现有关节风痛丸的基础上改剂型而来。本发明通过将现有的治疗关节炎的口服中药改剂型为外用凝胶贴，避免了肝脏的首过效应和药物对胃肠道的不良反应，同时还减少用药的个体差异，提高了患病部位的血药浓度，从而能更迅速、准确地发挥疗效，与现有药物相比，本发明还具有使用方便、依从性高等优点。
Description
技术领域
本发明属于制药领域，具体涉及一种用于治疗关节炎的外用凝胶贴。
背景技术
CN1823910A公开了一种用于风湿性筋骨酸痛、关节痛、四肢麻木的中药制剂，它是在“关节风痛丸”的基础上改剂型而来，“关节风痛丸”收载于中药部颁标准，标准号WS3-B-1126-92，它由豨莶草、狗脊、伸筋草、秦艽等10味中药材制成。部颁标准上的制备方法是将豨莶草、秦艽、独活用70％乙醇渗漏提取；五加皮、防己粉碎成细粉；鸡血藤、狗脊、桑枝、老鹳草、伸筋草加水煎煮提取，制成丸剂。
现有的剂型均为口服制剂，临床应用中，该药物具有很强的止痛、抗炎、抗肿胀活性，但也容易引起恶心、呕吐、腹痛腹泻等明显的胃肠道不良反应。
外用药物通过透皮吸收发挥作用，避免了药物在胃肠道的吸收、降解，因此可明显减轻药物副作用，另外，外用药物避免了肝脏的首过效应，可直接作用于患处，能提高患病部位的血药浓度，减少用药的个体差异，而且外用药还具有使用方便、依从性高等优点，是治疗风湿、类风湿关节炎的理想剂型。
发明内容
本发明的目的是针对现有口服中成药副作用大，服用不方便等问题，提供一种用于治疗关节炎的外用凝胶贴。
上述目的是通过以下技术方案实现的：
一种用于治疗关节炎的外用凝胶贴，它由以下重量份数的中药材制成：豨莶草100-200份、狗脊50-150份、伸筋草50-150份、秦艽50-150份、鸡血藤50-100份、防己50-150份、老鹳草50-100份、桑枝50-150份、五加皮20-80份、独活20-80份。
优选地，所述中药材的重量份数是：豨莶草138份、狗脊104份、伸筋草104份、秦艽104份、鸡血藤70份、防己104份、老鹳草70份、桑枝104份、五加皮52份、独活52份。
优选地，所述制备方法包括以下步骤：
1)以上药材，先加水蒸馏5-10小时，收集挥发油备用，然后继续加水煎煮提取1-4次，合并提取液并浓缩成相对密度为1.10～1.25的稠膏，冷至室温，加乙醇使含醇量达30-80％，搅匀后静置沉降，取上清液并浓缩至相对密度为1.35～1.40的稠膏；
2)将挥发油、稠膏和辅料混匀，制成凝胶基质，将凝胶基质摊涂于裱背材料上，即得凝胶贴。
进一步优选地，所述含醇量为70％，指重量含量。
进一步优选地，所述辅料由以下重量配比的成分组成：聚丙烯酸钠(骨架材料)100-500份、聚乙烯吡咯烷酮(凝胶材料)10-50份、交联聚维酮(凝胶材料)10-50份、氢氧化铝(交联剂)10-50份、枸橼酸(交联剂)10-50份、甘油(保湿剂)1000-2000份、山梨醇(保湿剂)10-50份、丙二醇(促渗剂)100-500份、月桂氮卓酮(促渗剂)100-200份、乙二胺四乙酸二钠(螯合剂)5-20份、羟苯乙酯(防腐剂)5-20份、薄荷脑(芳香剂、促渗剂)10-50份、纯化水(溶剂)2000-5000份。
进一步优选地，所述辅料由以下重量配比的成分组成：聚丙烯酸钠300份、聚乙烯吡咯烷酮30份、交联聚维酮30份、氢氧化铝30份、枸橼酸20份、甘油1000份、山梨醇30份、丙二醇300份、月桂氮卓酮150份、乙二胺四乙酸二钠15份、羟苯乙酯15份、薄荷脑30份、纯化水2500份。
进一步优选地，所述凝胶基质的制备方法是：将聚丙烯酸钠、交联聚维酮、氢氧化铝、甘油、丙二醇、月桂氮卓酮、羟苯乙酯、薄荷脑和步骤1)收集的挥发油搅拌混匀；将聚乙烯吡咯烷酮、枸橼酸、山梨醇、乙二胺四乙酸二钠、纯化水和步骤1)得到的稠膏搅拌混匀；然后再一起搅拌均质，制成凝胶基质。
本发明的有益效果是：
1)本发明将现有的治疗关节炎的口服中药改剂型为外用凝胶贴，避免了肝脏的首过效应和药物对胃肠道的不良反应，同时还减少用药的个体差异，提高了患病部位的血药浓度，从而能更迅速、准确地发挥疗效，与现有药物相比，本发明还具有使用方便、依从性高等优点。
2)本发明还具有很好的透皮吸收效果以及很高的镇痛药理活性，其镇痛作用接近于扶他林乳膏，能很好地缓解关节炎临床症状。
附图说明
图1是凝胶贴体外透皮吸收的累积透过量-时间曲线。
具体实施方式
以下通过实施例对本发明进行详细说明。
实施例1
处方：
豨莶草138g、狗脊104g、伸筋草104g、秦艽104g、鸡血藤70g、防己104g、老鹳草70g、桑枝104g、五加皮52g、独活52g。
制备方法：
1)以上药材，先加水蒸馏6小时，收集挥发油备用，然后继续加水煎煮提取3次，每次1小时，合并两次提取液并浓缩成相对密度为1.20(冷测)的稠膏，冷至室温，加乙醇使含醇量达40％(重量)，搅匀后静置沉降，取上清液并浓缩至相对密度为1.35(冷测)的稠膏。
2)制备凝胶基质，辅料如下：
聚丙烯酸钠200g、聚乙烯吡咯烷酮50g、交联聚维酮50g、氢氧化铝20g、枸橼酸30g、甘油1500g、山梨醇50g、丙二醇500g、月桂氮卓酮100g、乙二胺四乙酸二钠5g、羟苯乙酯5g、薄荷脑20g、纯化水2000g。
将聚丙烯酸钠、交联聚维酮、氢氧化铝、甘油、丙二醇、月桂氮卓酮、羟苯乙酯、薄荷脑和步骤1)收集的挥发油搅拌混匀；将聚乙烯吡咯烷酮、枸橼酸、山梨醇、乙二胺四乙酸二钠、纯化水和步骤1)得到的稠膏搅拌混匀；然后再一起搅拌均质，制成凝胶基质。
3)将凝胶基质摊涂于裱背材料上，即得凝胶贴。
实施例2
处方与实施例1相同。
制法：
1)以上药材，先加水蒸馏8小时，收集挥发油备用，然后继续加水煎煮提取2次，每次2小时，合并两次提取液并浓缩成相对密度为1.15(冷测)的稠膏，冷至室温，加乙醇使含醇量达70％(重量)，搅匀后静置沉降，取上清液并浓缩至相对密度为1.35(冷测)的稠膏。
2)制备凝胶基质，辅料如下：
聚丙烯酸钠300g、聚乙烯吡咯烷酮30g、交联聚维酮30g、氢氧化铝30g、枸橼酸20g、甘油1000g、山梨醇30g、丙二醇300g、月桂氮卓酮150g、乙二胺四乙酸二钠15g、羟苯乙酯15g、薄荷脑30g、纯化水2500g。
将聚丙烯酸钠、交联聚维酮、氢氧化铝、甘油、丙二醇、月桂氮卓酮、羟苯乙酯、薄荷脑和步骤1)收集的挥发油搅拌混匀；将聚乙烯吡咯烷酮、枸橼酸、山梨醇、乙二胺四乙酸二钠、纯化水和步骤1)得到的稠膏搅拌混匀；然后再一起搅拌均质，制成凝胶基质。
3)将凝胶基质摊涂于裱背材料上，即得凝胶贴。
实施例3
处方与实施例1相同。
制法：
1)以上药材，先加水蒸馏10小时，收集挥发油备用，然后继续加水煎煮提取4次，第一次1.5小时，第二次1小时，第三次和第四次各0.5小时，合并两次提取液并浓缩成相对密度为1.10(冷测)的稠膏，冷至室温，加乙醇使含醇量达55％(重量)，搅匀后静置沉降，取上清液并浓缩至相对密度为1.35(冷测)的稠膏。
2)制备凝胶基质，辅料如下：
聚丙烯酸钠450g、聚乙烯吡咯烷酮15g、交联聚维酮15g、氢氧化铝40g、枸橼酸40g、甘油1200g、山梨醇15g、丙二醇150g、月桂氮卓酮180g、乙二胺四乙酸二钠20g、羟苯乙酯15g、薄荷脑40g、纯化水2300g。
将聚丙烯酸钠、交联聚维酮、氢氧化铝、甘油、丙二醇、月桂氮卓酮、羟苯乙酯、薄荷脑和步骤1)收集的挥发油搅拌混匀；将聚乙烯吡咯烷酮、枸橼酸、山梨醇、乙二胺四乙酸二钠、纯化水和步骤1)得到的稠膏搅拌混匀；然后再一起搅拌均质，制成凝胶基质。
3)将凝胶基质摊涂于裱背材料上，即得凝胶贴。
对比例
参照CN1823910A的方法对中药材进行提取，即，豨莶草、秦艽、独活用70％乙醇渗漏提取；五加皮、防己用70％乙醇回流提取；鸡血藤、狗脊、桑枝、老鹳草、伸筋草加水煎煮提取，提取液浓缩后再用95％乙醇醇沉。将各部分的提取液浓缩成稠膏后加入实施例1中的辅料制成凝胶贴。
试验例
1.体外透皮吸收实验
以小鼠离体腹部皮肤为渗透屏障，采用Franz扩散池，将处理好的大鼠皮肤固定于扩散池的两室之间，精密称取实施例1～3和对比例制备的凝胶基质1g于供给室，生理盐水为接收介质。分别于1、2、4、6、8、12h取样，测定接收液中的防己碱含量，并计算累积透过率，结果见表1。
防己碱HPLC色谱条件如下：固定相为Agilent XDB-C18(5μm，4.6×250mm)，流动相为乙腈-甲醇-水-冰乙酸(35：34：30：1)，检测波长280nm，流速1.0mL/min，柱温30℃，进样量20μL。
表1凝胶贴体外透皮吸收的累积透过率(％)
累积透过量-时间曲线结果见图1，结果显示，本发明制备的凝胶贴具有较好的透皮吸收效果，12小时的累积透过率可达30％以上。
2.本发明药物对乙酸刺激所致小鼠疼痛的影响
关节风痛丸含有多种解毒镇痛类药物，能明显改善关节炎的疼痛症状，因此选择小鼠疼痛模型评价外用制剂对疗效的影响。
SPF级昆明小鼠60只，雌雄各半，体重20-24g，随机分为6组，分别为空白对照组、扶他林乳膏组、实施例1、2、3药物组和对比例药物组，每组10只。剃去各组小鼠背部毛3cm×3cm，然后6％硫化钠溶液进行脱毛处理，脱毛后扶他林乳膏组去毛区皮肤给药扶他林0.5g/kg，实施例1、2、3药物组和对比例药物组去毛区皮肤贴凝胶贴一片(3cm×3cm，相当于2.35g生药材/kg)，空白对照组贴不含药物的凝胶贴，每天换药一次，连续7天。末次给药后，参照徐淑云《药理实验方法学》小鼠醋酸扭体法建立小鼠疼痛模型，各组小鼠腹腔注射0.6％醋酸0.2mL。
开始计时，记录注射冰醋酸后30min内小鼠出现扭体反应的潜伏期和扭体次数，结果见表2。
表2各组小鼠的扭体潜伏期和次数
与扶他林乳膏组相比，＊P＜0.05，＊＊P＜0.01。
从以上结果可以看出，与空白对照组相比，扶他林乳膏组和各药物组都能显著延长小鼠模型的扭体潜伏期、减少扭体次数，说明都有镇痛作用，但是与扶他林乳膏组相比，仅实施例2无论是潜伏期还是扭体次数都没有显著差异(P>0.05)，说明实施例2的镇痛作用最接近于扶他林乳膏，而对比例与扶他林乳膏组相比二者都具有极显著差异(P＜0.01)，说明对比例的镇痛作用最差。
Claims (2)
1.一种用于治疗关节炎的外用凝胶贴，其特征在于由以下重量份数的中药材制成：豨莶草138份、狗脊104份、伸筋草104份、秦艽104份、鸡血藤70份、防己104份、老鹳草70份、桑枝104份、五加皮52份、独活52份，
制备方法包括以下步骤：
1)以上药材，先加水蒸馏8小时，收集挥发油备用，然后继续加水煎煮提取2次，每次2小时，合并提取液并浓缩成相对密度为1.15的稠膏，冷至室温，加乙醇使含醇量达70％，搅匀后静置沉降，取上清液并浓缩至相对密度为1.35的稠膏；
2)将挥发油、稠膏和辅料混匀，制成凝胶基质，将凝胶基质摊涂于裱背材料上，即得凝胶贴，
所述辅料由以下重量配比的成分组成：聚丙烯酸钠300份、聚乙烯吡咯烷酮30份、交联聚维酮30份、氢氧化铝30份、枸橼酸20份、甘油1000份、山梨醇30份、丙二醇300份、月桂氮卓酮150份、乙二胺四乙酸二钠15份、羟苯乙酯15份、薄荷脑30份、纯化水2500份。
2.如权利要求1所述用于治疗关节炎的外用凝胶贴，其特征在于所述凝胶基质的制备方法是：将聚丙烯酸钠、交联聚维酮、氢氧化铝、甘油、丙二醇、月桂氮卓酮、羟苯乙酯、薄荷脑和步骤1)收集的挥发油搅拌混匀；将聚乙烯吡咯烷酮、枸橼酸、山梨醇、乙二胺四乙酸二钠、纯化水和步骤1)得到的稠膏搅拌混匀；然后再一起搅拌均质，制成凝胶基质。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911139615.1A CN110755479B (zh) | 2019-11-20 | 2019-11-20 | 一种用于治疗关节炎的外用凝胶贴 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911139615.1A CN110755479B (zh) | 2019-11-20 | 2019-11-20 | 一种用于治疗关节炎的外用凝胶贴 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110755479A CN110755479A (zh) | 2020-02-07 |
| CN110755479B true CN110755479B (zh) | 2021-08-03 |
Family
ID=69338721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911139615.1A Active CN110755479B (zh) | 2019-11-20 | 2019-11-20 | 一种用于治疗关节炎的外用凝胶贴 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110755479B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823910A (zh) * | 2005-12-15 | 2006-08-30 | 北京阜康仁生物制药科技有限公司 | 关节风痛制剂及新的制备方法 |
| CN102772590A (zh) * | 2012-07-23 | 2012-11-14 | 广东省中医院 | 一种中药组合物及凝胶膏剂和制备方法 |
| CN109966366A (zh) * | 2019-05-17 | 2019-07-05 | 上海市光华中西医结合医院(上海市光华医院) | 一种清热消肿止痛的凝胶贴膏及其制备方法 |
-
2019
- 2019-11-20 CN CN201911139615.1A patent/CN110755479B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823910A (zh) * | 2005-12-15 | 2006-08-30 | 北京阜康仁生物制药科技有限公司 | 关节风痛制剂及新的制备方法 |
| CN102772590A (zh) * | 2012-07-23 | 2012-11-14 | 广东省中医院 | 一种中药组合物及凝胶膏剂和制备方法 |
| CN109966366A (zh) * | 2019-05-17 | 2019-07-05 | 上海市光华中西医结合医院(上海市光华医院) | 一种清热消肿止痛的凝胶贴膏及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110755479A (zh) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101933991B (zh) | 一种镇痛抗炎药物及其制备方法 | |
| CN100500196C (zh) | 一种重楼总皂苷的制备方法 | |
| CN101199586B (zh) | 一种用于紫癜的药物 | |
| CN106176784A (zh) | 一种用于皮炎的药物组合物、应用、制剂及其制备方法 | |
| CN101347477B (zh) | 用于治疗类风湿性关节炎的药物组合物 | |
| CN110755479B (zh) | 一种用于治疗关节炎的外用凝胶贴 | |
| CN1899316B (zh) | 中药微乳制剂及其制备方法 | |
| CN110025705A (zh) | 一种治疗特应性皮炎的中药组合物及其制备方法和应用 | |
| CN102139072B (zh) | 一种治疗妇科炎症的中药制剂 | |
| CN110859914B (zh) | 一种治疗口腔溃疡的中药贴膜 | |
| CN111375038B (zh) | 一种治疗银屑病的中药泡浴组合物、其制备方法及应用 | |
| CN101524407B (zh) | 一种治疗妇科疾病的外用药物组合物及其制备方法 | |
| CN107569528A (zh) | 一种治疗肝炎的药物组合物、药物制剂及应用和制备方法 | |
| CN108210651B (zh) | 一种用于治疗糖尿病肾病的天然药物组合物及其制备方法 | |
| CN108143800B (zh) | 一种治疗高血压心力衰竭的中药组合物 | |
| CN101396435A (zh) | 一种治疗胃病的中药及其制备方法和应用 | |
| CN116763834B (zh) | 一种治疗关节痛的中药组合物、制剂及制备方法和应用 | |
| CN102423323B (zh) | 一种治疗风湿病的复方药物及其制备方法 | |
| CN116870076B (zh) | 一种抗炎镇痛中药组合物及其制备方法与应用 | |
| CN102940621A (zh) | 甲基阿魏酸在制备预防和治疗肝纤维化药物中的应用 | |
| CN113712999B (zh) | 一种壮药血党干膏粉在制备抗炎镇痛药物中的应用 | |
| CN102284036A (zh) | 骨筋丸胶囊及其制备方法 | |
| CN110279829B (zh) | 消肿止痛组合物在制备治疗痔疮药物中的用途 | |
| CN100534482C (zh) | 治疗血管性头痛的软胶囊 | |
| CN106620070A (zh) | 一种治疗骨关节病变的药物组合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |